Reimbursement of ancillary costs incurred by a subject under the program:

1. (1) does not constitute an undue inducement to participate in a clinical trial;
2. (2) is not considered coercion or the exertion of undue influence to participate in a clinical trial; and
3. (3) shall be deemed to accomplish parity in access to clinical trials and remove barriers to participation in clinical trials for financially burdened subjects.

(Source: P.A. 103-227, eff. 6-30-23.)